Poland· PL-100502500
Dasatinib Accord Healthcare
A dasatinib product containing dasatinibum, registered in Poland by Accord Healthcare S.L.U.. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Dasatinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EA02 (dasatinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Dasatinib · ATC L01EA02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of dasatinib costs, country by country.
Normalised to the WHO defined daily dose (0.1 g), the median price runs from $1.57 in France to $48.85 in Switzerland — a ×31 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Dasatinib · price per daily dose (0.1 g)
USD · FX 28 Sept 2026
- CH Switzerland$48.85
- FR France$1.57
The record
At a glance
URPL (Poland)- Active substance
- Dasatinibum
- Manufacturer
- Accord Healthcare S.L.U.
- Country
- Poland (PL)
- ATC code
- L01EA02
- ATC class
- Dasatinib
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05055565799246
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
797 interactions on record for dasatinib.
Graded by severity as the source publishes them — 245 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dasatinib · interactions on record
797 records
- 245 severe
- 479 moderate
- 13 minor
- 60 info
Most severe, free to view
- CimetidineA02BA01severe
- RanitidineA02BA02severe
- FamotidineA02BA03severe
- NizatidineA02BA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EA02
Dasatinib, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1700cf94-26b1-4303-91b5-91680faaaf28 GET /v1/drugs/1700cf94-26b1-4303-91b5-91680faaaf28?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "80 mg",
"packaging": "05055565799246 ¦ Rpz ¦ EU/1/24/1839/013 ¦ 157538\n30 tabl.\nRpz ¦ EU/1/24/1839/016 ¦ 157539\n56 tabl. w blistrze perforowanym\nRpz ¦ EU/1/24/1839/015 ¦ 157540\n30 tabl. w blistrze perforowanym\nRpz ¦ EU/1/24/1839/014 ¦ 157541\n56 tabl.",
"substance": "Dasatinibum 80 mg",
"common_name": "Dasatinibum",
"pl_product_id": "100502500",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about dasatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.